Irinotecan sucrosofate - Merrimack/PharmaEngine

Drug Profile

Irinotecan sucrosofate - Merrimack/PharmaEngine

Alternative Names: Irinotecan liposome injection - Merrimack; MM-398; nal-IRI; Nano-irinotecan; Nanoliposomal irinotecan - Merrimack/PharmaEngine; Nanoliposomal irinotecan injection - Merrimack/PharmaEngine; Onivyde; pegylated liposomal irinotecan hydrochloride trihydrate; PEP-02

Latest Information Update: 18 Jan 2017

Price : $50

At a glance

  • Originator HERMES BioSciences
  • Developer Merrimack Pharmaceuticals; PharmaEngine; Shire; University of California at San Francisco
  • Class Alkaloids; Antineoplastics; Camptothecins; Small molecules
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Pancreatic cancer
  • Phase II Colorectal cancer; Gastric cancer
  • Phase I Glioma; Solid tumours

Most Recent Events

  • 08 Jan 2017 Ipsen enter definitive agreement with Merrimack Pharmaceuticals for rights to irinotecan sucrosofate in USA
  • 18 Oct 2016 Registered for Pancreatic cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) in European Union, Iceland, Norway, Liechtenstein (IV)
  • 11 Oct 2016 Final efficacy data from the phase III NAPOLI-1 trial in Pancreatic cancer presented at the 41st European Society for Medical Oncology Congress (ESMO-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top